Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium

Gara Arteaga-Henríquez, Maria S Simon, Bianka Burger, Elif Weidinger, Annemarie Wijkhuijs, Volker Arolt, Tom K Birkenhager, Richard Musil, Norbert Müller, Hemmo A Drexhage, Gara Arteaga-Henríquez, Maria S Simon, Bianka Burger, Elif Weidinger, Annemarie Wijkhuijs, Volker Arolt, Tom K Birkenhager, Richard Musil, Norbert Müller, Hemmo A Drexhage

Abstract

Low-grade inflammation plays a role not only in the pathogenesis of major depressive disorder (MDD) but probably also in the poor responsiveness to regular antidepressants. There are also indications that anti-inflammatory agents improve the outcomes of antidepressants. Aim: To study whether the presence of low-grade inflammation predicts the outcome of antidepressants, anti-inflammatory agents, or combinations thereof. Methods: We carried out a systematic review of the literature on the prediction capability of the serum levels of inflammatory compounds and/or the inflammatory state of circulating leukocytes for the outcome of antidepressant/anti-inflammatory treatment in MDD. We compared outcomes of the review with original data (collected in two limited trials carried out in the EU project MOODINFLAME) on the prediction capability of the inflammatory state of monocytes (as measured by inflammatory gene expression) for the outcome of venlafaxine, imipramine, or sertraline treatment, the latter with and without celecoxib added. Results: Collectively, the literature and original data showed that: 1) raised serum levels of pro-inflammatory compounds (in particular of CRP/IL-6) characterize an inflammatory form of MDD with poor responsiveness to predominately serotonergic agents, but a better responsiveness to antidepressant regimens with a) (add-on) noradrenergic, dopaminergic, or glutamatergic action or b) (add-on) anti-inflammatory agents such as infliximab, minocycline, or eicosapentaenoic acid, showing-next to anti-inflammatory-dopaminergic or lipid corrective action; 2) these successful anti-inflammatory (add-on) agents, when used in patients with low serum levels of CRP/IL-6, decreased response rates in comparison to placebo. Add-on aspirin, in contrast, improved responsiveness in such "non-inflammatory" patients; 3) patients with increased inflammatory gene expression in circulating leukocytes had a poor responsiveness to serotonergic/noradrenergic agents. Conclusions: The presence of inflammation in patients with MDD heralds a poor outcome of first-line antidepressant therapies. Immediate step-ups to dopaminergic or glutamatergic regimens or to (add-on) anti-inflammatory agents are most likely indicated. However, at present, insufficient data exist to design protocols with reliable inflammation parameter cutoff points to guide such therapies, the more since detrimental outcomes are possible of anti-inflammatory agents in "non-inflamed" patients.

Keywords: anti-inflammatory therapy; antidepressant therapy; inflammation; major depression; therapy prediction.

Figures

Figure 1
Figure 1
Flow diagram of the systematic research. See materials and methods section for further explanation.

References

    1. Müller N, Hofschuster E, Ackenheil M, Mempel W, Eckstein R. Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Prog Neuropsychopharmacol Biol Psychiatry (1993) 17(5):713–30. 10.1016/0278-5846(93)90055-W
    1. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci (1998) 62(7):583–606. 10.1016/S0024-3205(97)00990-9
    1. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol (1999) 461:199–233. 10.1007/978-0-585-37970-8_12
    1. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol (2001) 11(3):203–8. 10.1016/S0924-977X(01)00081-5
    1. Myint A-M, Leonard BE, Steinbusch HWM, Kim Y-K. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord (2005) 88(2):167–73. 10.1016/j.jad.2005.07.008
    1. Irwin MR, Miller AH. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun (2007) 21(4):374–83. 10.1016/j.bbi.2007.01.010
    1. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci (2008) 9(1):46–56. 10.1038/nrn2297
    1. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med (2009) 71(2):171–86. 10.1097/PSY.0b013e3181907c1b
    1. Miller AH. Depression and immunity: a role for T cells? Brain Behav Immun (2010) 24(1):1–8. 10.1016/j.bbi.2009.09.009
    1. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry (2010) 67(5):446–57. 10.1016/j.biopsych.2009.09.033
    1. Drexhage RC, Weigelt K, van Beveren N, Cohen D, Versnel MA, Nolen WA, et al. Immune and neuroimmune alterations in mood disorders and schizophrenia. Int Rev Neurobiol (2011) 101:169–201. 10.1016/B978-0-12-387718-5.00007-9
    1. Eyre HA, Stuart MJ, Baune BT. A phase-specific neuroimmune model of clinical depression. Prog Neuropsychopharmacol Biol Psychiatry (2014) 54:265–74. 10.1016/j.pnpbp.2014.06.011
    1. Müller N. Immunology of major depression. NIM (2014) 21(2–3):123–30. 10.1159/000356540
    1. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun (2015) 49:206–15. 10.1016/j.bbi.2015.06.001
    1. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol (2016) 16(1):22–34. 10.1038/nri.2015.5
    1. Grosse L, Hoogenboezem T, Ambrée O, Bellingrath S, Jörgens S, de Wit HJ, et al. Deficiencies of the T and natural killer cell system in major depressive disorder: T regulatory cell defects are associated with inflammatory monocyte activation. Brain Behav Immun (2016) 54:38–44. 10.1016/j.bbi.2015.12.003
    1. Gibney SM, Drexhage HA. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmune Pharmacol (2013) 8(4):900–20. 10.1007/s11481-013-9462-8
    1. Bergink V, Gibney SM, Drexhage HA. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry (2014) 75(4):324–31. 10.1016/j.biopsych.2013.09.037
    1. Poletti S, de Wit H, Mazza E, Wijkhuijs AJM, Locatelli C, Aggio V, et al. Th17 cells correlate positively to the structural and functional integrity of the brain in bipolar depression and healthy controls. Brain Behav Immun (2017) 61:317–25. 10.1016/j.bbi.2016.12.020
    1. Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, et al. The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol (2012) 92(5):959–75. 10.1189/jlb.0212100
    1. Grosse L, Carvalho LA, Wijkhuijs AJM, Bellingrath S, Ruland T, Ambrée O, et al. Clinical characteristics of inflammation-associated depression: monocyte gene expression is age-related in major depressive disorder. Brain Behav Immun (2015) 44:48–56. 10.1016/j.bbi.2014.08.004
    1. Gałecki P, Talarowska M. Inflammatory theory of depression. Psychiatr Pol (2018) 52(3):437–47. 10.12740/PP/76863
    1. Medina-Rodriguez EM, Lowell JA, Worthen RJ, Syed SA, Beurel E. Involvement of innate and adaptive immune systems alterations in the pathophysiology and treatment of depression. Front Neurosci (2018) 12. 10.3389/fnins.2018.00547
    1. Pundiak TM, Case BG, Peselow ED, Mulcare L. Discontinuation of maintenance selective serotonin reuptake inhibitor monotherapy after 5 years of stable response: a naturalistic study. J Clin Psychiatry (2008) 69(11):1811–7. 10.4088/JCP.v69n1117
    1. Dell’Osso B, Palazzo MC, Oldani L, Altamura AC. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci Ther (2011) 17(6):723–32. 10.1111/j.1755-5949.2010.00217.x
    1. Furukawa TA, Salanti G, Atkinson LZ, Leucht S, Ruhe HG, Turner EH, et al. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open (2016) 6(7):e010919. 10.1136/bmjopen-2015-010919
    1. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet (2009) 373(9665):746–58. 10.1016/S0140-6736(09)60046-5
    1. Frick LR, Rapanelli M. Antidepressants: influence on cancer and immunity? Life Sci (2013) 92(1):525–32. 10.1016/j.lfs.2013.01.020
    1. Gałecki P, Mossakowska-Wójcik J, Talarowska M. The anti-inflammatory mechanism of antidepressants—SSRIs, SNRIs. Prog Neuropsychopharmacol Biol Psychiatry (2018) 80(Pt C):291–94. 10.1016/j.pnpbp.2017.03.016
    1. Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A, et al. Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatrica Scandinavica (2014) 123(3):163–79. 10.1111/acps.12211
    1. Müller N. Immunological aspects of the treatment of depression and schizophrenia. Dialogues Clin Neurosci (2017) 19:1.
    1. Husain MI, Strawbridge R, Stokes PR, Young AH. Anti-inflammatory treatments for mood disorders: systematic review and meta-analysis. J Psychopharmacol (Oxford) (2017) 31(9):1137–48. 10.1177/0269881117725711
    1. Adzic M, Brkic Z, Mitic M, Francija E, Jovicic MJ, Radulovic J, et al. Therapeutic strategies for treatment of inflammation-related depression. Curr Neuropharmacol (2018) 16(2):176–209. 10.2174/1570159X15666170828163048
    1. Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M. Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry (2016) 77(4):e457–66. 10.4088/JCP.15r09984
    1. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol (2015) 15(2):104–16. 10.1038/nri3793
    1. Palacio JR, Markert UR, Martínez P. Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm Res (2011) 60(7):695–704. 10.1007/s00011-011-0323-8
    1. Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep (2011) 13(6):467–75. 10.1007/s11920-011-0232-0
    1. Vermeiden M, Mulder PG, van den Broek WW, Bruijn JA, Birkenhäger TK. A double-blind randomized study comparing plasma level-targeted dose imipramine and high-dose venlafaxine in depressed inpatients. J Psychiatr Res (2013) 47(10):1337–42. 10.1016/j.jpsychires.2013.05.029
    1. Bakkalbasi N, Bauer K, Glover J, Wang L. Three options for citation tracking: Google Scholar, Scopus and Web of Science. Biomed Digit Libr (2006) 3:7. 10.1186/1742-5581-3-7
    1. Jha MK, Minhajuddin A, Gadad B, Greer T, Grannemann B, Soyombo A, et al. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. Psychoneuroendocrinology (2017) 78:105–13. 10.1016/j.psyneuen.2017.01.023
    1. Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry (2014) 171(12):1278–86. 10.1176/appi.ajp.2014.14010094
    1. Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2008) 32(2):445–50. 10.1016/j.pnpbp.2007.09.015
    1. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Katsuki A, Atake K, et al. Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder: IL-6 and SSRI response. Hum Psychopharmacol (2013) 28(5):466–70. 10.1002/hup.2333
    1. Manoharan A, Rajkumar RP, Shewade DG, Sundaram R, Muthuramalingam A, Paul A. Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine. Hum Psychopharmacol (2016) 31(3):178–84. 10.1002/hup.2525
    1. Chang HH, Lee IH, Gean PW, Lee S-Y, Chi MH, Yang YK, et al. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun (2012) 26(1):90–5. 10.1016/j.bbi.2011.07.239
    1. Haroon E, Daguanno AW, Woolwine BJ, Goldsmith DR, Baer WM, Wommack EC, et al. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology (2018) 95:43–9. 10.1016/j.psyneuen.2018.05.026
    1. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry (2009) 33(4):722–6. 10.1016/j.pnpbp.2009.03.020
    1. Martinez JM, Garakani A, Yehuda R, Gorman JM. Proinflammatory and “resiliency” proteins in the CSF of patients with major depression. Depress Anxiety (2012) 29(1):32–8. 10.1002/da.20876
    1. Harley J, Luty S, Carter J, Mulder R, Joyce P. Elevated C-reactive protein in depression: a predictor of good long-term outcome with antidepressants and poor outcome with psychotherapy. J Psychopharmacol (2010) 24(4):625–6. 10.1177/0269881109102770
    1. Yang J, Wang N, Yang C, Shi J, Yu H, Hashimoto K. Serum interleukin-6 is a predictive biomarker for ketamine’s antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry (2015) 77(3):e19–e20. 10.1016/j.biopsych.2014.06.021
    1. Gupta R, Gupta K, Tripathi AK, Bhatia MS, Gupta LK. Effect of mirtazapine treatment on serum levels of brain-derived neurotrophic factor and tumor necrosis factor-α in patients of major depressive disorder with severe depression. Pharmacology (2016) 97(3–4):184–8. 10.1159/000444220
    1. Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, et al. Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof of concept study. Mol Psychiatry (2016) 21(1):71–9. 10.1038/mp.2015.22
    1. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression. JAMA Psychiatry (2013) 70(1):31–41. 10.1001/2013.jamapsychiatry.4
    1. Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE, Meyer M, et al. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry (2018) 8(1):27. 10.1038/s41398-017-0073-7
    1. Husain MI, Chaudhry IB, Husain N, Khoso AB, Rahman RR, Hamirani MM, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol (2017) 31(9):1166–75. 10.1177/0269881117724352
    1. Porcu M, Urbano MR, Verri WA, Barbosa DS, Baracat M, Vargas HO, et al. Effects of adjunctive N-acetylcysteine on depressive symptoms: modulation by baseline high-sensitivity C-reactive protein. Psychiatry Res (2018) 263:268–74. 10.1016/j.psychres.2018.02.056
    1. Hasebe K, Gray L, Bortolasci C, Panizzutti B, Mohebbi M, Kidnapillai S, et al. Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor. Acta Neuropsychiatrica (2017) 29(6):337–46. 10.1017/neu.2017.2
    1. Panizzutti B, Bortolasci C, Hasebe K, Kidnapillai S, Gray L, Walder K, et al. Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression. Acta Neuropsychiatrica (2018) 30(6):334–41. 10.1017/neu.2018.13
    1. Powell TR, Schalkwyk LC, Heffernan AL, Breen G, Lawrence T, Price T, et al. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. Eur Neuropsychopharmacol (2013) 23(9):1105–14. 10.1016/j.euroneuro.2012.09.009
    1. Guilloux J-P, Bassi S, Ding Y, Walsh C, Turecki G, Tseng G, et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacology (2015) 40(3):701–10. 10.1038/npp.2014.226
    1. Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline “predictors” and longitudinal “targets”. Neuropsychopharmacology (2013) 38(3):377–85. 10.1038/npp.2012.191
    1. Cattaneo A, Ferrari C, Uher R, Bocchio-Chiavetto L, Riva MA, Pariante CM. Absolute measurements of macrophage migration inhibitory factor and interleukin-1-β mRNA levels accurately predict treatment response in depressed patients. Int J Neuropsychopharmacol (2016) 19(10):pyw045. 10.1093/ijnp/pyw045
    1. Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Tréziny C, Verrier L, et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry (2012) 2(11):e185. 10.1038/tp.2012.112
    1. Carvalho LA, Bergink V, Sumaski L, Wijkhuijs J, Hoogendijk WJ, Birkenhager TK, et al. Inflammatory activation is associated with a reduced glucocorticoid receptor alpha/beta expression ratio in monocytes of inpatients with melancholic major depressive disorder. Transl Psychiatry (2014) 4(1):e344. 10.1038/tp.2013.118
    1. American Psychiatric Association Diagnostic and statistical manual of mental disorders (4th ed., text rev). Washington, DC: American Psychiatric Association; (2000).
    1. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I disorders (SCID I). New York: Biometric Research Department; (1997).
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 23:56–62. 10.1037/t04100-000
    1. Müller N, Krause D, Barth R, Myint AM, Weidinger E, Zill P, et al. Childhood adversity and current stress are related to pro- and anti-inflammatory cytokines in major depression. J Affect Disord (2019) 253:270–76. 10.1016/j.jad.2019.04.088
    1. Vogels RJ, Koenders MA, van Rossum EF, Spijker AT, Drexhage HA. T Cell Deficits and overexpression of hepatocyte growth factor in anti-inflammatory circulating monocytes of middle-aged patients with bipolar disorder characterized by a high prevalence of the metabolic syndrome. Front Psychiatry (2017) 8(34):1–11. 10.3389/fpsyt.2017.00034
    1. Mesman E, Hillegers MH, Ambree O, Arolt V, Nolen WA, Drexhage HA. Monocyte activation, brain-derived neurotrophic factor (BDNF), and S100B in bipolar offspring: a follow-up study from adolescence into adulthood. Bipolar Disord (2015) 17(1):39–49. 10.1111/bdi.12231
    1. Snijders G, Schiweck C, Mesman E, Grosse L, De Wit H, Nolen WA, et al. A dynamic course of T cell defects in individuals at risk for mood disorders. Brain Behav Immun (2016) 58:11–7. 10.1016/j.bbi.2016.05.007
    1. Nakayama K. Effect of paroxetine on extracellular serotonin and dopamine levels in the prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol (2002) 365(2):102–5. 10.1007/s00210-001-0497-7
    1. Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand (2017) 135(5):373–87. 10.1111/acps.12698
    1. Hanisch UW. Microglia as a source and target of cytokines. Glia (2002) 40(2):140–55. 10.1002/glia.10161
    1. Czéh B, Nagy SA. Clinical findings documenting cellular and molecular abnormalities of glia in depressive disorders. Front Mol Neurosci (2018) 11(56):1–16. 10.3389/fnmol.2018.00056
    1. Sato K. Effects of microglia on neurogenesis. Glia (2015) 63(8):1394–1405. 10.1002/glia.22858
    1. Hökfelt T, Stanic D, Sanford SD, Gatlin JC, Nilsson I, Paratcha G, et al. NPY and its involvement in axon guidance, neurogenesis, and feeding. Nutrition (2008) 24(9):860–68. 10.1016/j.nut.2008.06.010
    1. Slavich GM, Way BM, Eisenberger NI, Taylor SE. Neural sensitivity to social rejection is associated with inflammatory responses to social stress. Proc Natl Acad Sci USA (2010) 107(33):14817–22. 10.1073/pnas.1009164107
    1. Poletti S, Leone G, Hoogenboezem TA, Ghiglino D, Vai B, de Wit H, et al. Markers of neuroinflammation influence measures of cortical thickness in bipolar depression. Psychiatry Res Neuroimaging (2019) 285:64–6. 10.1016/j.pscychresns.2019.01.009
    1. Benedetti F, Poletti S, Hoogenboezem TA, Mazza E, Ambree O, de Wit H, et al. Inflammatory cytokines influence measures of white matter integrity in bipolar disorder. J Affect Disord (2016) 202:1–9. 10.1016/j.jad.2016.05.047
    1. Baldeón Rojas L, Weigelt K, de Wit H, Ozcan B, van Oudenaren A, Sempértegui F, et al. Study on inflammation-related genes and microRNAs, with special emphasis on the vascular repair factor HGF and miR-574-3p, in monocytes and serum of patients with T2D. Diabetol Metab Syndr (2016) 8(6):1–12. 10.1186/s13098-015-0113-5
    1. Beck G, Brinkkoetter P, Hanusch C, Schulte J, van Ackern K, van der Woude FJ, et al. Clinical review: immunomodulatory effects of dopamine in general inflammation. Crit Care (2004) 8(6):485–91. 10.1186/cc2879
    1. Loix S, KocK MD, Henin P. The anti-inflammatory effects of ketamine: state of the art. Acta Anaesthesiol Belg (2011) 62(1):47–58..
    1. Zhu C-B, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology (2006) 31(10):2121–31. 10.1038/sj.npp.1301029
    1. Zhu C-B, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology (2010) 35(13):2510–20. 10.1038/npp.2010.116
    1. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry (2007) 12(11):988–1000. 10.1038/sj.mp.4002006
    1. Walker FR. A critical review of the mechanism of action for the selective serotonin reuptake inhibitors: do these drugs possess anti-inflammatory properties and how relevant is this in the treatment of depression? Neuropharmacology (2013) 67:304–17. 10.1016/j.neuropharm.2012.10.002
    1. Brooks JD, Norris PC, Dennis EA. Effects of omega-3 fatty acids on lipid metabolism and signaling using lipidomic analyses. FASEB J (2010) 24:475.1-475.1. 10.1096/fasebj.24.1_supplement.475.1
    1. Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci (2001) 98(25):14669–74. 10.1073/pnas.251341998
    1. Shin SS, Dixon CE. Oral fish oil restores striatal dopamine release after traumatic brain injury. Neurosci Lett (2011) 496(3):168–71. 10.1016/j.neulet.2011.04.009
    1. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci (2013) 34(3):167–77. 10.1016/j.tips.2013.01.001
    1. De Cristóbal J, Moro MA, Dávalos A, Castillo J, Leza JC, Camarero J, et al. Neuroprotective effect of aspirin by inhibition of glutamate release after permanent focal cerebral ischaemia in rats. J Neurochem (2001) 79(2):456–9. 10.1046/j.1471-4159.2001.00600.x
    1. De Cristóbal J, Cárdenas A, Lizasoain I, Leza JC, Fernández-Tomé P, Lorenzo P, et al. Inhibition of glutamate release via recovery of ATP levels accounts for a neuroprotective effect of aspirin in rat cortical neurons exposed to oxygen-glucose deprivation. Stroke (2002) 33(1):261–7. 10.1161/hs0102.101299
    1. Becking K, Haarman BCM, Grosse L, Nolen WA, Claes S, Arolt V, et al. The circulating levels of CD4+ t helper cells are higher in bipolar disorder as compared to major depressive disorder. J Neuroimmunol (2018) 319:28–36. 10.1016/j.jneuroim.2018.03.004
    1. Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK, et al. Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry (2004) 61(5):450–8. 10.1001/archpsyc.61.5.450
    1. Yüksel C, Öngür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry (2010) 68(9):785–94. 10.1016/j.biopsych.2010.06.016
    1. Gigante AD, Bond DJ, Lafer B, Lam RW, Young LT, Yatam LN. Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. Bipolar Disord (2012) 14(5):478–87. 10.1111/j.1399-5618.2012.01033.x
    1. Jun C, Choi Y, Lim SM, Bae S, Hong YS, Kim JE, et al. Disturbance of the glutamatergic system in mood disorders. Exp Neurobiol (2014) 23(1):28–35. 10.5607/en.2014.23.1.28
    1. Perlman K, Benrimoh D, Israel S, Rollins C, Brown E, Tunteng J-F, et al. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. J Affect Disord (2019) 243:503–15. 10.1016/j.jad.2018.09.067
    1. Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry—Novel perspectives on brain disorders. Nat Rev Neurol (2019) 15(6):317–28. 10.1038/s41582-019-0174-4

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren